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Objective: Although laparoscopic surgery is widely utilized in the treatment of endometrial cancer, its
efﬁcacy in staging the cancer is not well established. The aim of this study was to compare staging
endometrial cancer with laparoscopic and conventional open methods.
Materials and Methods: From January 2002 to June 2012, 151 patients (70 treated by laparoscopy and 81
by laparotomy) diagnosed with endometrial cancer were enrolled. This was a retrospective cohort review
of endometrial cancer surgically staged using laparoscopy or laparotomy in the Department of Obstetrics
and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
Results: The two groups did not signiﬁcantly differ in patient age, body mass index, previous obstetrical
history, or amount of previous abdominal surgery. No differences between the surgical cohorts were
observed in relation to cancer status, including stage, grade, myometrial invasion, lymphovascular space
invasion, lymph node involvement, and recurrence rate. The laparoscopic approach had less intra-
operative blood loss, longer operative time, lower uterine weight, number of removed lymph nodes, and
shorter hospital stay.
Conclusion: Our preliminary results showed that the laparoscopic method for staging endometrial cancer
was technically feasible and efﬁcient.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Endometrial cancer (EC) is the most common female genital
malignancy in developed countries, accounting for 4% of cancers in
female patients. EC occurs most commonly in women with a mean
age> 50 years. The standard treatment of EC is surgery according to
the staging system of the International Federation of Obstetrics and
Gynecology (FIGO). The traditional procedures of staging surgery
include cytology of peritoneal washings, total abdominal hyster-
ectomy, and bilateral salpingo-oophorectomy. Staging surgery may
also include pelvic and/or para-aortic lymphadenectomy. The
beneﬁt of pelvic and para-aortic lymphadenectomy is not well
established in low-risk EC; this includes those with myometrial
invasion that does not extend past half of the depth of the myo-
metrium, Grade 1e2 endometrioid adenocarcinoma, and no lym-
phovascular space invasion (LVSI) [1e3].s and Gynecology, National
uth Road, Taipei 100, Taiwan.
bstetrics & Gynecology. PublishedThe role of laparoscopy in surgical staging has become
increasingly important in recent decades. Numerous studies have
shown signiﬁcantly less morbidity, shorter hospitalization, less
pain, and quicker recovery with laparoscopic staging [4e10].
However, the therapeutic value of laparoscopy has not been
conﬁrmed until now. Many previous studies may have been inef-
fective in evaluating the efﬁcacy of laparoscopic staging as they had
a wide range of conversion to laparotomy at 0e36.4% [11e20].
The aim of this retrospective study was to compare the safety,
morbidity, and EC recurrence rate between surgical staging with
laparoscopy and laparotomy.Materials and methods
We retrospectively reviewed the data recorded for all patients
with EC treated by laparoscopic or open surgery between June 2002
and April 2012 in the National Taiwan University Hospital, Taipei,
Taiwan.
Inclusion criteria were as follows: (1) tissue-proven endometrial
carcinoma; (2) tumor mass 2 cmwithout regional or distal lymphby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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standard surgical staging was performed, consisting of total hys-
terectomy, bilateral salpingo-oophorectomy, pelvic lymphadenec-
tomy and/or para-aortic lymphadenectomy; and (4) preoperative
evaluation showed the tumor to be clinically conﬁned to the uter-
ine corpus, which deﬁnes clinical Stage 1. No patient received
radical hysterectomy although some patients were conﬁrmed Stage
2 or higher by postoperative pathological reports.
Pelvic lymphadenectomy consisted of removing the lymphatic
tissue from over the external iliac artery and vein, and from the
obturator fossa, above the obturator nerve. Para-aortic lymphade-
nectomy consisted of removing the lymphatic tissue from the area
over the abdominal aorta and inferior vena cava, below the level of
the inferior mesenteric artery.
Controls were selected from consecutive cases who had un-
dergone surgical staging of EC through laparotomy since 2002 and
met the above inclusion criteria. Patient characteristics included
age, body mass index (BMI), parity, virginity status, and history of
previous abdominal surgery. Oncological data included cancer
grade, surgical stage (as deﬁned by FIGO, 2009), depth of myo-
metrial invasion, LVSI, and recurrence rate.
Statistical analysis
SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Descriptive statistics were presented as
means± standard deviations or percentages. Means were
compared by Student t test, and proportions were compared by c2
or Fisher's exact tests, as appropriate. All calculated p values were
two-tailed, and p < 0.05 was considered statistically signiﬁcant.
Results
Between January 2002 and June 2012, 151 women underwent
staging surgery for EC (81 by laparotomy and 70 by laparoscopy). In
the laparoscopy group, all the operations were performed lapa-
roscopically; none of the cases were converted to laparotomy.
These cases were compared with a historical cohort of 81 patients
with EC who had undergone surgical staging through laparotomy
during the same time period. Pelvic lymphadenectomy was per-
formed in all patients in both the laparoscopic and laparotomic
groups. Para-aortic lymphadenectomy was performed in two pa-
tients (2.8%) in the laparoscopic group and in 11 patients (13.6%)
who underwent laparotomy.
Characteristics of the two study groups are summarized in
Table 1. Therewas no signiﬁcant difference between the two groups
with regards to age, obstetric history, BMI, percentage of previous
abdominal surgery, histological grade of EC, or EC stage. There was
no signiﬁcant difference in the percentages of previous abdominal
surgery between the two groups (27.1% in the laparoscopic group
and 25.9% in the laparotomic group, p ¼ 0.974). The percentages ofTable 1








Patient age (y) 55.3 (29e80) 53.4 (28e75) 0.248
Gestation 2.65 (0e8) 2.94 (0e8) 0.147
Parity 2.09 (0e7) 2.14 (0e5) 0.147
Body mass index (kg/m2) 25.0 (16e38) 25.4 (13e44) 0.354
Virgins 5 (7.1) 6 (7.4) 0.965
Previous abdominal surgery 19 (27.1) 21 (25.9) 0.974
Data are presented as n (%) or mean (range).previous laparotomy, such as cesarean section, appendectomy,
adnexal surgery, and myomectomy, between the two groups did
not show a signiﬁcant difference (23% in the laparoscopic group
and 20% in those who had staging by laparotomy, p ¼ 0.717).
However, no patient had previously undergone more than three
laparotomies. Table 2 shows the intraoperative parameters of the
two groups. Although laparoscopic approach had a signiﬁcantly
longer operative time than laparotomy (159 minutes vs. 140 mi-
nutes, p ¼ 0.003), it had less intraoperative blood loss (78 mL vs.
248 mL, p < 0.001). Three patients in the laparotomic group had
excessive blood loss> 500mL and required blood transfusion. None
of the patients in the laparoscopic group required blood trans-
fusion. Additional ﬁndings included a signiﬁcantly smaller uterine
weight (187 g vs. 288 g, p¼ 0.003) and fewer lymph nodes resected
(15 vs. 20, p ¼ 0.002) with the laparoscopic approach as opposed to
laparotomy. Those who underwent laparoscopy had a shorter
average hospital stay when compared to those who underwent
laparotomy (5 days vs. 10 days, p ¼ 0.012). There was no signiﬁcant
difference in complication rate between the laparoscopic and lap-
arotomic groups (11.4% vs. 18.5%, p ¼ 0.089). No vascular compli-
cations or bowel injuries were noted during the laparoscopic
staging surgeries. Two cases of intraoperative bladder injury were
reported, and cystorrhaphy was performed successfully by lapa-
roscopic approach. However, the rate of lymphocyst infection was
signiﬁcantly lower in the laparoscopic group (1.4% vs. 12.3% in the
open group, p < 0.001).
Table 3 shows the oncological results of the two surgical
methods. In both groups, most patients had Stage 1 and Grade 1 EC
with invasion into less than half of the myometrium. Two patients
(2.9%) in the laparoscopic group and six (7.4%) in the open group
were upstaged to Stage 3 due to pelvic lymph node metastases.
Although signiﬁcantly more patients in the open group underwent
para-aortic lymphadenectomy (8.6% vs. 1.4% of the laparoscopic
group, p < 0.001), there was no signiﬁcant difference of EC recur-
rence rate between the two groups (2.9% in the laparoscopy group
vs. 2.5% in the laparotomy group, p ¼ 0.882). Approximately one-
quarter of the patients in each group received postoperative adju-
vant therapy (27.1% vs. 29.6%, p ¼ 0.578). Two patients in the
laparoscopic group had conﬁrmed recurrence, both with metasta-
ses to the lung, at 6 months and 12 months postoperatively. One
patient expired from sepsis 16 months after laparoscopic staging
surgery. Comparatively, of those who underwent laparotomy, four
patients had recurrence at 3 months to 6 years after primary
treatment. The recurrent focus was located over the vagina, lung,
chest wall, neck, or abdominal lymph nodes. Two patients in the
laparotomic group expired at 1.6 years and 2 years after primary
treatment. The recurrent rate and overall survival between both
groups did not differ signiﬁcantly.
Furthermore, we analyzed the oncological outcomes of the
subgroup of FIGO Stage 2 and Stage 3 (Table 4). There were four and
14 patients in the laparoscopic and laparotomic groups, respec-
tively. It still showed no signiﬁcant difference in recurrent rate and
overall survival between the groups.
Discussion
This retrospective, single-institutional study demonstrates that
the laparoscopic management of EC with lymphadenectomy is a
feasible, effective, and safe method. There is no need for conversion
to laparotomy with proper patient selection criteria. The applica-
tion of laparoscopy in EC staging is gaining more importance, and
some studies have shown that laparoscopy has been performed
more than laparotomy in gynecological oncology services [21]. The
trend of this change is based on the advantages of laparoscopy,
including lower costs to the hospital, shorter hospital stays, and
Table 2








Intraoperative blood loss (mL) 78 (30e300) 248 (50e1500) <0.001
Operative time (min) 159 (81e275) 140 (80e190) 0.003
Uterine weight (g) 186.8 (55e405) 287.5 (40e1360) 0.003
No. of pelvic lymph nodes 15 (2e58) 20 (4e50) 0.002
Hospital stays (d) 5 (3e11) 10 (5e28) 0.012
Intra- and postoperative
complications
8 (11.4) 15 (18.5) 0.089
Wound infection 0 (0) 2 (2.4)
Vaginitis 4 (5.7) 1 (1.2)
Lymphocyst infection 1 (1.4) 10 (12.3)
Urinary tract infection 1 (1.4) 1 (1.2)
Ileus 0 (0) 1 (1.2)
Bladder perforation 2 (2.8) 0 (0)
Data are presented as n (%) or mean (range).
Table 4









1 2 (50.0) 8 (57.1)
2 2 (50.0) 2 (18.5)
3 0 4 (11.1)
Myometrial invasion 0.028
No 1 (25.0) 0 (0)
1/2 thickness 3 (75.0) 5 (35.7)
>1/2 thickness 0 (0) 9 (64.3)
LVSI 0.093
No 3 (75.0) 4 (28.6)
Yes 1 (25.0) 10 (71.4)
Lymph node metastasis 0.800
No 2 (50) 8 (57.1)
Yes 2 (50) 6 (42.9)
Adjuvant therapy 0.689
No 1 (25.0) 1 (7.1)
Brachytherapy 0 (0) 1 (7.1)
External beam radiation
& brachytherapy
3 (75.0) 11 (78.7)
Chemotherapy 0 (0) 1 (7.1)
Recurrence 0.423
No 4 (100) 12 (85.7)
Yes 0 (0) 2 (14.3)
Death 0.582
No 4 (100) 13 (92.9)
Yes 0 (0) 1 (7.1)
Data are presented as n (%).
L.-H. Chu et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 188e192190fewer postoperative complications [22e25]. Numerous retrospec-
tive and few prospective studies have provided evidence of the
feasibility and short-term safety of laparoscopic staging
[5,22,26e31]. The Gynecology Oncology Group LAP2 Phase III trial
enrolled 2181 patients with median follow-up time of 59 months.
This trial demonstrated that there was no increased risk of recur-
rence at 3 years in those who underwent laparoscopy versus lap-
arotomy, and the 5-year overall survival was identical in both
groups [26]. In this trial, however, the conversion from laparoscopy
to laparotomy occurred in 23.7% of cases. Conversion to laparotomy
was associated with increasing BMI, metastatic disease, and
increasing patient age. A small percentage of patients from bothTable 3









1 54 (77.1) 57 (70.4)
2 13 (18.6) 15 (18.5)
3 3 (4.3) 9 (11.1)
Stage 0.123
1 66 (94.3) 68 (84.0)
2 1 (1.4) 5 (6.2)
3 3 (4.3) 8 (9.8)
Myometrial invasion 0.923
No 20 (28.6) 21 (25.9)
 1/2 thickness 39 (55.7) 46 (56.8)
> 1/2 thickness 11 (15.7) 14 (17.3)
LVSI 0.947
No 55 (78.6) 64 (79.0)
Yes 15 (21.4) 17 (21.0)
Lymph node metastasis 0.213
No 68 (97.1) 75 (92.6)
Yes 2 (2.9) 6 (7.4)
Adjuvant therapy 0.578
No 51 (72.9) 57 (70.4)
Brachytherapy 10 (14.2) 10 (12.3)
External beam radiation
& brachytherapy
9 (12.9) 12 (14.8)
Chemotherapy 0 (0) 2 (2.5)
Recurrence 0.514
No 68 (97.1) 77 (95.1)
Yes 2 (2.9) 4 (4.9)
Death 0.917
No 69 (98.6) 80 (98.8)
Yes 1 (1.4) 1 (1.2)
5-year progression-free survival rate 97.1 96.3 e
5-year overall survival rate 98.6 97.5 e
Data are presented as n, n (%), or mean (range).groups was upstaged from preoperative clinical Stage 1 to post-
operative Stage  2. There are still insufﬁcient data describing the
safety and long-term EC control when using the laparoscopic
approach in the treatment of Stage  2 cancer. According to risk
stratiﬁcation from the Mayo Clinic, Scottsdale, AZ, USA, the rates of
lymphatic spread increase when nonendometrioid type, high-
grade cancer, with a large tumor diameter (> 2 cm) and deep
myometrial invasion is present [32]. The eight upstaged patients
with lymph node metastases from our study had higher rates of
Grade 3 cancer (12.5% vs. 7.3%), myometrial invasion of > 1/2 depth
(75% vs. 12.6%), and LVSI (75% vs. 17.9%) when compared to those
without lymph node metastases. In addition, the survival effect of
para-aortic lymphadenectomy in endometrial cancer (SEPAL)
study, a retrospective cohort analysis, conﬁrmed the therapeutic
role of pelvic and para-aortic lymph node dissection, as it pro-
longed overall survival (hazard ratio 0.53; p < 0.001) when
compared to pelvic lymphadenectomy alone [33]. One retrospec-
tive cohort analysis concluded that para-aortic lymphadenectomy
should be performed if one or more of the following conditions are
present: (1) positive pelvic nodes (as assessed by frozen section);
(2) Type 2 EC; or (3) deep myometrial invasion (> 50% of myo-
metrial thickness) [34].
Our data conﬁrmed the safety of laparoscopic management in
early EC. Intraoperatively, blood loss was signiﬁcantly lower in the
laparoscopic group, with no patients requiring blood transfusion
during or after surgery. Additionally, operative time was longer for
laparoscopy. Both of these ﬁndings are compatible with ﬁndings
from prior studies [4e10]. We found that the rate of lymphocyst
infection was also signiﬁcantly lower in the laparoscopic group
(1.4% vs. 12.3% in the open group, p < 0.001). According to previous
studies, the incidence of lymphocyst formation is higher after open
surgery than after laparoscopic surgery [1,20,22,35e53]. The risk
factors for lymphocyst formation include inadequate closure of
lymphatic vessels, lymph node metastases, postoperative radio-
therapy, absence of retroperitoneal drainage, and the number of
lymph nodes removed, especially deep inguinal nodes [40,41]. A
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group, which is in the range of 8.2e27.1 nodes removed in previous
studies [1,4,5,8,15,20,22,27,35e39,42e51]. No patient required
conversion to laparotomy, which compares with previously recor-
ded conversion rates of 0e36.4% [11e20]. The mean uterine weight
was lower in the laparoscopic group in order to maintain uterine
integrity and prevent cancer cell spillage from the uterine cavity
during its vaginal removal.
There was no signiﬁcant difference in the recurrence rates be-
tween the two groups (2.9% in the laparoscopic group vs. 2.5% in the
open group, p ¼ 0.882). The survival data was limited due to the
relatively small cohort. Only two patients in the laparotomy group
and one in laparoscopy group died from cancer recurrence during
follow-up. However, unlike other studies, the site of cancer recur-
rence in our laparoscopy group seemed to be distant metastasis,
with recurrence in the lung [31,52,53]. These results may be due to
our second limitation, wherein the criteria of postoperative adju-
vant brachytherapy might not have been consistent in the two
groups for fear of vaginal stump recurrence in the laparoscopic
group. The percentage of deep myometrial invasion was slightly
lower in the laparoscopic group, but the rate of brachytherapy was
slightly higher, which may have inﬂuenced the recurrence data.
In conclusion, our current data conﬁrmed the role of laparos-
copy in the management of early EC. It also proved the safety and
efﬁcacy of a laparoscopic approach with lower rates of blood
transfusion and nearly equal rates of intraoperative morbidity. The
recurrence data in the laparoscopic group were not inferior when
compared with those for laparotomy. The long-term survival data
may need more patients and longer follow-up time for further
evaluation.
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